Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Janux Therapeutics, Inc.JANX · Entity 4864 | Chief Strategy Officer | January 02, 2025 | January 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Janux Therapeutics, Inc.
Report date January 02, 2025 · Filed January 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,000 |
Reported balance
After 2025-01-02 transaction · row 1
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 28,000 · Balance 28,000 F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.24 · Expires 2035-01-01 | Direct | 98,000 |
Reported balance
After 2025-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-02 · Grant · Acquired 98,000 · Balance 98,000 F2: 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026.
F2: 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2025 Filed Jan 3, 2025 20:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 98,000 | $0.00 Strike: $53.24 | $0.00 |
DisclosureSEC source: 0001415889-25-000674 · form4-01032025_080105.xml · derivative · entry 2 Robinson Byron · CIK 0001914899 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,000 Underlying: Common Stock · 98,000 shares Expires 2035-01-01 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 20:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000674 · form4-01032025_080105.xml · nonDerivative · entry 1 Robinson Byron · CIK 0001914899 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 16:53 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 151,500 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-24-000438 · doc4.xml · derivative · entry 1 Robinson Byron · CIK 0001914899 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,500 Underlying: Common Stock · 151,500 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:35 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001209191-23-001885 · doc4.xml · derivative · entry 1 Robinson Byron · CIK 0001914899 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 17:06 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $16.81 | $0.00 |
DisclosureSEC source: 0001209191-22-015616 · doc4.xml · derivative · entry 1 Robinson Byron · CIK 0001914899 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 28, 2023 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.